NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $49.06 +1.18 (+2.46 %) (As of 05/20/2019 04:00 PM ET)Previous Close$47.88Today's Range$47.05 - $49.4152-Week Range$40.25 - $80.92Volume608,161 shsAverage Volume635,176 shsMarket Capitalization$1.66 billionP/E Ratio25.29Dividend YieldN/ABeta1.32 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania. Receive BEAT News and Ratings via Email Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAT Previous Symbol CUSIPN/A CIK1574774 Webwww.gobio.com Phone610-729-7000Debt Debt-to-Equity Ratio0.57 Current Ratio1.99 Quick Ratio1.84Price-To-Earnings Trailing P/E Ratio25.29 Forward P/E Ratio25.82 P/E GrowthN/A Sales & Book Value Annual Sales$399.47 million Price / Sales4.15 Cash Flow$3.3718 per share Price / Cash Flow14.55 Book Value$9.85 per share Price / Book4.98Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$42.82 million Net Margins11.86% Return on Equity23.36% Return on Assets11.95%Miscellaneous Employees1,500 Outstanding Shares33,804,000Market Cap$1.66 billion Next Earnings Date7/24/2019 (Estimated) OptionableOptionable BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions What is BioTelemetry's stock symbol? BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT." How were BioTelemetry's earnings last quarter? BioTelemetry Inc (NASDAQ:BEAT) released its earnings results on Thursday, April, 25th. The medical research company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The medical research company had revenue of $103.98 million for the quarter, compared to the consensus estimate of $104.17 million. BioTelemetry had a return on equity of 23.36% and a net margin of 11.86%. The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.39 earnings per share. View BioTelemetry's Earnings History. When is BioTelemetry's next earnings date? BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for BioTelemetry. What guidance has BioTelemetry issued on next quarter's earnings? BioTelemetry updated its FY 2019 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $446-450 million, compared to the consensus revenue estimate of $442.05 million. What price target have analysts set for BEAT? 6 analysts have issued 12 month price objectives for BioTelemetry's shares. Their predictions range from $64.00 to $95.00. On average, they anticipate BioTelemetry's stock price to reach $78.8333 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price. View Analyst Price Targets for BioTelemetry. What is the consensus analysts' recommendation for BioTelemetry? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry. Has BioTelemetry been receiving favorable news coverage? Media coverage about BEAT stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioTelemetry earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of BioTelemetry's key competitors? Some companies that are related to BioTelemetry include GN STORE NORD A/ADR (GNNDY), Charles River Laboratories Intl. (CRL), Insulet (PODD), DiaSorin (DSRLF), Sartorius (SARTF), Encompass Health (EHC), Exelixis (EXEL), GALAPAGOS NV/S (GLPG), Amarin (AMRN), PRA Health Sciences (PRAH), Medidata Solutions (MDSO), Nektar Therapeutics (NKTR), Hikma Pharmaceuticals (HKMPF), athenahealth (ATHN) and Chemed (CHE). What other stocks do shareholders of BioTelemetry own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Adobe (ADBE), Micron Technology (MU), Square (SQ), ABIOMED (ABMD), Netflix (NFLX), Alibaba Group (BABA), Veeva Systems (VEEV), Intuitive Surgical (ISRG) and Canopy Growth (CGC). Who are BioTelemetry's key executives? BioTelemetry's management team includes the folowing people: Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)Ms. Heather C. Getz, Exec. VP & CFO (Age 44)Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55) Who are BioTelemetry's major shareholders? BioTelemetry's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.70%), Dimensional Fund Advisors LP (3.94%), Macquarie Group Ltd. (2.25%), Eagle Asset Management Inc. (1.47%), Carillon Tower Advisers Inc. (1.42%) and Northern Trust Corp (1.39%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry. Which institutional investors are selling BioTelemetry stock? BEAT stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Kennedy Capital Management Inc., BlackRock Inc., Morgan Stanley, Rice Hall James & Associates LLC, Fiera Capital Corp, THB Asset Management and Columbus Circle Investors. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry. Which institutional investors are buying BioTelemetry stock? BEAT stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Rothschild & Co. Asset Management US Inc., Natixis, OppenheimerFunds Inc., Meritage Portfolio Management, Wellington Management Group LLP and Raymond James & Associates. View Insider Buying and Selling for BioTelemetry. How do I buy shares of BioTelemetry? Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTelemetry's stock price today? One share of BEAT stock can currently be purchased for approximately $49.06. How big of a company is BioTelemetry? BioTelemetry has a market capitalization of $1.66 billion and generates $399.47 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.94 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe. What is BioTelemetry's official website? The official website for BioTelemetry is http://www.gobio.com. How can I contact BioTelemetry? BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected] MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 310 (Vote Outperform)Underperform Votes: 266 (Vote Underperform)Total Votes: 576MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.